Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Prometheus Biosciences Inc
(NQ:
RXDX
)
199.92
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 15, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Prometheus Biosciences Inc
< Previous
1
2
3
4
Next >
Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
December 08, 2022
Via
Benzinga
Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today
December 07, 2022
U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee meeting beginning to weigh on investors’ minds.
Via
Benzinga
Dow Edges Higher; Prometheus Biosciences Shares Jump
December 07, 2022
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 0.5% on Wednesday.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 07, 2022
Via
Benzinga
Nasdaq Drops 75 Points; Crude Oil Down 2%
December 07, 2022
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping 75 points on Wednesday.
Via
Benzinga
Why Shares of Prometheus Biosciences Slumped This Week
December 02, 2022
The company's lead pipeline candidate is facing competition from a Pfizer-backed drug.
Via
The Motley Fool
Expert Ratings for Prometheus Biosciences
August 29, 2022
Within the last quarter, Prometheus Biosciences (NASDAQ:RXDX) has observed the following analyst ratings:
Via
Benzinga
Analyst Ratings for Prometheus Biosciences
August 29, 2022
Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter:
Via
Benzinga
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
December 07, 2022
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC...
Via
Benzinga
Dow Bounces Back From Morning Selloff
December 07, 2022
The Dow Jones Industrial Average is trying to claw back from the market's multi-day selloff. Meanwhile, the S&P 500 Index and Nasdaq Composite Index continue to flag near breakeven.
Via
Talk Markets
Analyst Ratings for Prometheus Biosciences
May 13, 2022
Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter:
Via
Benzinga
PINS Stock Alert: What to Know as Pinterest and Elliott Strike a Deal
December 07, 2022
Pinterest (PINS) stock is on the move Wednesday as investors react to an agreement with Elliott Investment Management L.P.
Via
InvestorPlace
US Stocks Mixed; Dow Rises 50 points
December 07, 2022
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 50 points on Wednesday.
Via
Benzinga
Why Is Prometheus Biosciences (RXDX) Stock Up 175% Today?
December 07, 2022
Prometheus Biosciences (NASDAQ:RXDX) stock is rocketing higher on Wednesday after reporting results from two Phase 2 clinical trials.
Via
InvestorPlace
Prometheus Biosciences Catapults 176% On Promising Results In Irritable Bowel Disease
December 07, 2022
Prometheus Biosciences made waves Wednesday in irritable bowel disease.
Via
Investor's Business Daily
These 2 Nasdaq Stocks Knocked It Out of the Park Wednesday
December 07, 2022
Even as broader markets fell, these companies announced great news.
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 07, 2022
Via
Benzinga
Prometheus Biosciences Stock Skyrockets After Favorable Data From Ulcerative Colitis, Crohn's Disease Studies
December 07, 2022
Via
Benzinga
Oppenheimer Maintains Outperform Rating for Prometheus Biosciences: Here's What You Need To Know
October 04, 2022
Oppenheimer has decided to maintain its Outperform rating of Prometheus Biosciences (NASDAQ:RXDX) and raise its price target from $50.00 to $65.00. Shares of Prometheus Biosciences are trading down...
Via
Benzinga
Where Prometheus Biosciences Stands With Analysts
October 04, 2022
Over the past 3 months, 7 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Delta Air Lines To Rally Around 84%? Here Are 5 Other Price Target Changes For Tuesday
October 04, 2022
Raymond James raised Delta Air Lines, Inc. (NYSE: DAL) price target from $50 to $52. Raymond James analyst Savanthi Syth maintained a Strong Buy rating on the stock. Delta Air shares rose 0.7% to close...
Via
Benzinga
7 Top-Rated Biotech Stocks to Buy for Q4
September 15, 2022
A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter.
Via
InvestorPlace
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
August 30, 2022
Not all shares are slowing down alongside the industry group.
Via
Investor's Business Daily
SVB Leerink Slashes Price Target On This Stock By Over 73%, Plus This Analyst Predicts $56 For Toll Brothers
August 29, 2022
Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading.
Via
Benzinga
Ulta Beauty To $511? Here Are 5 Other Price Target Changes For Monday
August 29, 2022
Barclays boosted the price target on Ulta Beauty, Inc. (NASDAQ: ULTA) from $491 to $511. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Ulta Beauty shares fell 1% to...
Via
Benzinga
Where Prometheus Biosciences Stands With Analysts
August 12, 2022
Over the past 3 months, 4 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
July 18, 2022
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
July 20, 2022
Upgrades
Via
Benzinga
Prometheus Biosciences Stock Shows Rising Relative Strength
July 14, 2022
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022
June 10, 2022
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.